A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.
暂无分享,去创建一个
P. Haslett | Y. Qiu | F. Wijburg | Luying Pan | S. Rust | C. Breen | Jou-Ku Chung | A. Barbier | N. Nair | E. Tump | Simon A. Jones | J. de Ruijter | J. P. Marchal | Simon A Jones | Fiona Heap
[1] P. Haslett,et al. A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA. , 2016, The Journal of pediatrics.
[2] P. Haslett,et al. A novel LC-MS/MS assay for heparan sulfate screening in the cerebrospinal fluid of mucopolysaccharidosis IIIA patients. , 2016, Bioanalysis.
[3] D. Whiteman,et al. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome) , 2015, Orphanet Journal of Rare Diseases.
[4] P. Haslett,et al. Methods of neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome. , 2013, JIMD reports.
[5] M. Heartlein,et al. Safety evaluation of chronic intrathecal administration of heparan N-sulfatase in juvenile cynomolgus monkeys , 2012, Drug Delivery and Translational Research.
[6] M. Grootenhuis,et al. Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome) , 2011, Orphanet journal of rare diseases.
[7] R. Wevers,et al. Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype‐phenotype correlations , 2010, Annals of neurology.
[8] Alan S. Kaufman,et al. Kaufman Assessment Battery for Children , 2010 .
[9] D. Rapoport,et al. Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I , 2009, Pediatrics.
[10] J. Turner,et al. Programmable Intrathecal Opioid Delivery Systems for Chronic Noncancer Pain: A Systematic Review of Effectiveness and Complications , 2007, The Clinical journal of pain.
[11] C. Eng,et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) , 2006, Genetics in Medicine.
[12] J. Wittes,et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. , 2006, The Journal of pediatrics.
[13] M. Walker,et al. Complications of Intrathecal Baclofen Pumps in Children , 2003, Pediatric Neurosurgery.
[14] K. Follett,et al. A prospective study of catheter-related complications of intrathecal drug delivery systems. , 2000, Journal of pain and symptom management.
[15] Gary J. Robertson,et al. Bayley Scales of Infant and Toddler Development , 2017 .